You are here
Drugmaker Aiming for 25–30 New Drugs by 2022
HHS proposal designed to prevent ‘Shkrelis,’ not high drug prices overall
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.
Health plans expected to continue pushing for value-based payment arrangements.
Puts down $700 million to buy nearly 50% of Samsung.
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.
FDA Commissioner Says Agency Needs to Fill Data Gaps as It Looks to Increase Access to Targeted Therapies
Gottlieb spoke at the NCCN Policy Summit on the role of data analytics in drug trials
Some experts still opposed to “right to try” treatments
Agency plans to respond after receipt of letter of concern
But some in industry disagree with the idea
Clinical trial of NIH-developed vaccine will evaluate effectiveness of the new agent
Six states will also participate in the litigation